Article
The RAS-Effector Interaction as a Drug Target.
Cancer research - 15 Jan 2017
Keeton Adam B, Salter E Alan, Piazza Gary A
Abstract excerpt
About a third of all human cancers harbor mutations in one of the K-, N-, or HRAS genes that encode an abnormal RAS protein locked in a constitutively activated state to drive malignant transformation and tumor growth. Despite more than three decades of intensive research aimed at the discovery of RAS-directed therapeutics, there are no FDA-approved drugs that are broadly effective against RAS-driven cancers....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.